Rural Health Bridge: The biggest segment by size, facing challenges of trust, access, and affordability requiring last-mile innovation
The most common adverse events reported by those on tirzepatide compared with placebo, respectively, were diarrhea (18.4% vs 6.3%), nausea (17.0% vs 6.5%), and constipation (14.8% vs 6%)
By slowing gastric emptying, increasing satiety signaling, and improving post-meal glucose control, it reduces caloric intake for many users
This contrasts with oral tirzepatide formulations, which use absorption enhancers to improve bioavailability
Clinical Evidence Systematic Review Description of Study The SELECT trial (N = 17,609) was a phase IIIb, multinational, multicentre, randomized, double-blind, parallel-group, placebo-controlled trial that evaluated the effect of semaglutide 2.4 mg subcutaneous injection compared with placebo in reducing the risk of MACE (CV death, nonfatal MI, or nonfatal stroke) in patients with established CVD and overweight or obesity and without diabetes
The First Few Weeks: Getting Acquainted Both semaglutide and tirzepatide are powerful medications known as GLP-1 (glucagon-like peptide-1) receptor agonists
